Suboxone lawsuit claims allege that buprenorphine/naloxone film dissolved in the mouth caused tooth decay, erosion and tooth loss, and that dental warnings came too late. Federal cases are consolidated in MDL 3092 before Judge J. Philip Calabrese in the Northern District of Ohio, with 2,022 actions pending on October 1, 2026. No settlement has been announced; a first trial is proposed for March 2028.
Updates on Suboxone Lawsuit
Quick Answer: The Suboxone dental injury lawsuit update for August 2026 centers on MDL 3092, the federal litigation involving claims that Suboxone (buprenorphine/naloxone) sublingual film caused serious dental injuries. Plaintiffs allege prolonged exposure to the film contributed to tooth decay, dental erosion, fractured teeth and tooth loss, and that adequate dental warnings were not provided [...]
Key facts (as of October 2026)
- Oct. 1, 2026: 2,022 actions pending in MDL 3092 (JPML).
- July 13, 2026 – Jan. 15, 2027: Deposition window for the 50-case Core Discovery Pool.
- Jan. 29, 2027: Scheduled selection of a 15-case trial pool (five per side plus five at random).
- March 2028: Proposed first trial setting under Second Amended Case Management Order No. 15.
- Jan. 12, 2022: FDA warned of dental problems with buprenorphine medicines dissolved in the mouth, citing 305 cases, 131 of them serious.
What the Suboxone lawsuits claim
Plaintiffs allege that Suboxone film is acidic and can cause dental erosion and decay, as the JPML's February 5, 2024 transfer order summarizes, and that the makers failed to warn patients and prescribers. Named defendants include Indivior entities, Aquestive Therapeutics and Reckitt Benckiser entities. FDA's 2022 safety communication reported tooth decay, cavities, oral infections and tooth loss, including 26 cases in patients with no prior dental history. FDA required a new warning but stated that the medicines' benefits clearly outweigh the risks.
Where the litigation stands
Second Amended Case Management Order No. 15, entered March 27, 2026, sets the bellwether protocol: depositions in a 50-case Core Discovery Pool from July 13, 2026 to January 15, 2027, selection of a 15-case trial pool on January 29, 2027, and a proposed first trial setting in March 2028 that the court says it will reduce to an order later. The JPML counts actions rather than individual plaintiffs, so 2,022 is not a head count of claimants. No settlement or verdict had been reported as of October 2026.
Who may qualify
People who used the sublingual film and later needed fillings, crowns, root canals, extractions or implants for decay or erosion may qualify, particularly where dental records show a healthier baseline before treatment. Pharmacy records, dental charts and X-rays generally carry the most weight. Do not stop prescribed treatment without talking to your prescriber.
Deadlines and next steps
Statutes of limitations vary by state, and many apply a discovery rule tied to when the injury and its likely cause were known. Review the factors in the Suboxone settlement calculator, and see Suboxone settlement amounts for why no payout figures exist yet.
Frequently asked questions
Has the Suboxone litigation settled?
No settlement had been announced as of October 2026. The court's bellwether schedule calls for a 15-case trial pool to be chosen on January 29, 2027 and proposes a first trial setting in March 2028. Until a settlement or verdict exists, any per-claim dollar figure is a projection rather than an amount set by a court or agreement.
Does it matter whether I used the film or the tablet?
The MDL is titled for Suboxone film, and the JPML's transfer order describes allegations about the film. FDA's 2022 dental warning, however, covers buprenorphine medicines dissolved in the mouth generally, not only Suboxone film. Whether a particular product supports a claim depends on its manufacturer, the records available and state law, so keep pharmacy records that show the exact product.
How long after starting treatment did dental problems appear?
In the cases FDA reviewed, the median time to diagnosis was about two years (24.25 months), with a range from half a month to 182 months, and some problems appeared as soon as two weeks after treatment began. Because of that spread, dental records from before and during treatment are usually important evidence.
Sources
- U.S. FDA – FDA warns about dental problems with buprenorphine medicines dissolved in the mouth (Jan. 12, 2022)
- Judicial Panel on Multidistrict Litigation – Pending MDL Dockets by Actions Pending (Oct. 1, 2026)
- U.S. District Court, N.D. Ohio – MDL 3092, Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation
- JPML – Transfer Order, MDL 3092 (Feb. 5, 2024)
- U.S. District Court, N.D. Ohio – Second Amended Case Management Order No. 15, Bellwether Protocol (Mar. 27, 2026)
Filter Posts
Browse by Category
